RE:RE:RE:RE:RE:RE:A speculative thoughtI wonder why you both said that Taimed is lack of pipeline.
To my information, there are two drugs are under developed.
The first is TMB 607, TMB-607 is the only long-acting parenteral antiretroviral treatment for HIV, while all other available alternatives, such as Prezista, Reyataz and Kaletra, require one or two daily dosages administered orally.
Taimed filed IND and got approval from FDA on May 2016, and cooperated with Dr. J. Jacobson of Temple University to run phase I clinical trials since Dec 13, 2016, on that day the first patient was enrolled.
The other is TMB-365 (LM-52). The TMB-365 is an ibalizumab (TMB-355) based, IgG1-scaffold, anti-CD4 recombinant humanized monoclonal antibody used against HIV infections. The major medication or medicament of TMB-365 is mainly focused upon treatment and prevention against HIV infections (including opportunistic infections), said therapeutic and prophylactic usages or medical application. The TMB-365-relevant technology platforms of TMB-365 are licensed from Arron Diamond AIDS Research Center (ADARC) anchored at Rockefeller University (RU).
The study has been published on Oct 6, 2013 on Nature Biotechnology.
You can find that the viral coverage of TMB-365(LM52) is almost 100% compared with 90% of TMB-355 (90% is already the highest till now).
TMB-365 is going to file IND by the end of 2017.
You on can read the article by the following link:
https://www.taimedbiologics.com.tw/images/resource/association/LM52.pdf